Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous humanized anti-CD22 chimeric antigen receptor T cells
- Development stage
- Unknown
- Lead developer
- Beijing Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous humanized anti-CD22 chimeric antigen receptor (CAR) T cells represent a cell-based gene therapy designed to treat B-cell malignancies. This therapy involves collecting T cells from a patient (autologous), genetically modifying them to express a CAR that specifically targets the CD22 protein found on the surface of malignant B cells, and then reinfusing these modified T cells back into the patient. The humanized component aims to reduce immunogenicity. Upon reinfusion, these CAR-T cells recognize and bind to CD22-expressing cancer cells, leading to their destruction. The therapy is being investigated for conditions such as refractory or relapsed B acute lymphoblastic leukemia (B-ALL).
- Other names
- CD22 CAR-TCD-22 CAR-TCD 22 CAR-Tanti-CD22 CAR-T cellsanti-CD-22 CAR-T cellsanti-CD 22 CAR-T cellscar-t cells targeting cd22
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on Autologous humanized anti-CD22 chimeric antigen receptor T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous humanized anti-CD22 chimeric antigen receptor T cells.